Education
About Us
Working with TipRanks
Follow Us
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H (HK:9989)
:9989
RESEARCH TOOLSreports
Earnings Data
Report Date
Aug 30, 2025TBA (Not Confirmed)
Period Ending
2025 (Q2)Consensus EPS Forecast
0.02Last Year’s EPS
0.38Same Quarter Last Year
Moderate Sell
Based on 0 Analysts Ratings
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H (HK:9989) Earnings, Revenues Date & History
HK:9989 Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
HK:9989 Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Apr 25, 2025 | HK$4.18 | HK$4.13 | -1.20% |
Mar 28, 2025 | HK$4.37 | HK$4.31 | -1.37% |
Oct 30, 2024 | HK$4.22 | HK$4.17 | -1.18% |
Aug 30, 2024 | HK$3.20 | HK$3.24 | +1.25% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H (HK:9989) report earnings?
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H (HK:9989) is schdueled to report earning on Aug 30, 2025, TBA (Not Confirmed).
What is Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H (HK:9989) earnings time?
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H (HK:9989) earnings time is at Aug 30, 2025, TBA (Not Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is the P/E ratio of Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H stock?
The P/E ratio of Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H is N/A.
What is HK:9989 EPS forecast?
HK:9989 EPS forecast for the fiscal quarter 2025 (Q2) is 0.02.